← Stack Research Tool

Pair page

Kisspeptin with Testosterone

Mechanism-tag overlap and published literature for Kisspeptin and Testosterone, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.

Mechanism overlap

Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.

KISSPEPTIN TESTOSTERONE 1 UNIQUE TAGS 2 UNIQUE TAGS 0 SHARED
Kisspeptin unique endogenous-hpg-axis-master-regulator
Shared none
Testosterone unique androgenprimary-male-sex-hormone

Co-administration notes from the literature

Verbatim summary text pulled from each compound's profile data. Researchers studying Kisspeptin and Testosterone have published these mechanism-level observations. Not a co-administration recommendation.

Evidence level: mechanistic only

Conceptually, kisspeptin could maintain HPG axis tone during exogenous testosterone therapy (TRT), preventing testicular atrophy and preserving fertility. This is mechanistically plausible but not validated by controlled trials. Testosterone's negative feedback on the HPG axis acts downstream of kisspeptin at the hypothalamus and pituitary, and whether kisspeptin can overcome this feedback in TRT patients is an open question.

Quick facts

Kisspeptin

RouteIV infusion / SubQ (research)
Half-life~28 min (Kp-10); ~60+ min (Kp-54)
FDA statusNot approved; active Phase 2
WADANot specifically named
Full Kisspeptin profile →

Testosterone

RouteIM, SubQ, transdermal, oral (undecanoate), pellet
Half-lifeNot listed
FDA statusApproved (multiple formulations)
WADABanned (S1)
Full Testosterone profile →

Literature table

Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.

Year Compound Source Finding
2022KisspeptinThurston L, Hunjan T, Ertl N, Wall MB, Mills EG, Suladze S, et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(10):e2236131. PMID: 36227594. PMID 36227594human trial
2018KisspeptinTrevisan CM, Montagna E, de Oliveira R, Christofolini DM, Barbosa CP, Crandall KA, Bianco B. Kisspeptin/GPR54 System: What Do We Know About Its Role in Human Reproduction? Cell Physiol Biochem. 2018;49(4):1259-1276. PMID: 30205368. PMID 30205368human study
2017KisspeptinComninos AN, Wall MB, Demetriou L, Shah AJ, Clarke SA, Narayanaswamy S, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-719. PMID: 28112678. PMID 28112678human study
2014KisspeptinSkorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20(4):485-500. PMID: 24615662. PMID 24615662human study
2011KisspeptinChan YM, Butler JP, Pinnell NE, Pralong FP, Crowley WF Jr, Ren C, et al. Kisspeptin resets the hypothalamic GnRH clock in men. J Clin Endocrinol Metab. 2011;96(6):E908-915. PMID: 21470993. PMID 21470993human study
2009KisspeptinJayasena CN, Nijher GM, Chaudhri OB, Murphy KG, Ranger A, Lim A, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):… PMID 19820030human study
2005KisspeptinDhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy KG, Badman MK, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-6615. PMID: 16174713. PMID 16174713human study
2007KisspeptinLapatto R, Pallais JC, Zhang D, Chan YM, Mahan A, Cerrato F, et al. Kiss1−/− mice exhibit more variable hypogonadism than Gpr54−/− mice. Endocrinology. 2007;148(10):4927-4936. PMID: 17595229. PMID 17595229preclinical, in vivo
2015KisspeptinAbbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Nijher GM, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. J Clin Endocrinol Met… PMID 26192876preclinical, in vitro
2014KisspeptinJayasena CN, Abbara A, Comninos AN, Nijher GM, Christopoulos G, Narayanaswamy S, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-3677. PMID: 25036713. PMID 25036713preclinical, in vitro
2020KisspeptinAbbara A, Eng PC, Phylactou M, Clarke SA, Hunjan T, Roberts R, et al. Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. J Clin Invest. 2020;130(12):6739-6753. PMID: 33196464. PMID 33196464research article
2015KisspeptinClarke H, Dhillo WS, Jayasena CN. Comprehensive Review on Kisspeptin and Its Role in Reproductive Disorders. Endocrinol Metab (Seoul). 2015;30(2):124-141. PMID: 26194072. PMID 26194072research article
2007TestosteroneHaddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis. Mayo Clin Proc. 2007;82(1):29-39. PMID: 17285783. PMID 17285783systematic review
2015TestosteroneKaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Sex Med. 2015;3(4):269-279. PMID: 26797061. PMC4721027. PMID 26797061human trial, Phase 2
2018TestosteroneBhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364. PMID 29562364human study
2013TestosteroneFinkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022. PMID: 24024838. PMID 24024838human study
2008TestosteroneCoviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-919. PMID: 18160461. PMID 18160461human study
2001TestosteroneHarman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86(2):724-731. PMID: 11158037. PMID 11158037human study
2025TestosteroneWADA. 2025 Prohibited List. Section S1 — Anabolic Agents. World Anti-Doping Agency.regulatory / registry
2023TestosteroneLincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM Jr, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE; TRAVERSE Stu… PMID 37326322research article
2018TestosteroneMulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, Lightner DJ, Miner MM, Murad MH, Nelson CJ, Platz EA, Ramanathan LV, Lewis RW. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. PMID: 29601923. PMID 29601923research article
2016TestosteroneSnyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. PMID: 26886521. PMID 26886521research article
2016TestosteroneMorgentaler A, Zitzmann M, Traish AM, Fox AW, Jones TH, Maggi M, Arver S, Aversa A, Chan JC, Dobs AS, Hackett GI, Hellstrom WJ, Lim P, Lunenfeld B, Mskhalaya G, Schulman CC, Torres LO. Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Con… PMID 27313122research article
2016TestosteroneShoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016;5(6):834-843. PMID: 28078214. PMID 28078214research article

Related pair pages

More research context

Frequently asked

Have Kisspeptin and Testosterone been studied together?

Researchers have published mechanistic-level co-administration discussion of Kisspeptin and Testosterone. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.

What mechanisms do Kisspeptin and Testosterone share?

Kisspeptin and Testosterone do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.

What is the FDA status of Kisspeptin and Testosterone?

Kisspeptin: Not approved; active Phase 2. Testosterone: Approved (multiple formulations). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.

Where can I find the full research on Kisspeptin and Testosterone?

Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Kisspeptin profile and the Testosterone profile. The Kalios Stack Research Tool hub lists every compound covered.

Last updated: April 2026